Praxis Precision Medicines, Inc. (PRAX) Key Metrics
PRAX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $6.75B
- Enterprise value
- $7.12B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 144.7
- Price / book
- 5.9 10-yr median 3.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 2.81
PRAX key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsPRAX valuation Price multiples at each fiscal year-end price.
PRAX returns How much profit the business earns on the capital it uses.
PRAX per-share figures Results divided by the shares outstanding at year-end.
PRAX financial health Debt, liquidity and how easily interest is covered.
PRAX efficiency & capital use Working capital cycle and where the cash goes.
PRAX valuation history
PRAX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PRAX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PRAX cash returned to shareholders
PRAX price vs earnings per share
PRAX key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $6.63B | $1.38B | $146.9M | — | — | — | — | — |
| Enterprise value | $6.03B | $986.9M | $68.1M | — | — | — | — | — |
| Price / sales | — | 161.1 | 60.0 | — | — | — | — | — |
| Price / book | 7.6 | 3.1 | 2.1 | — | — | — | — | — |
| EV / sales | — | 115.4 | 27.8 | — | — | — | — | — |
| Earnings yield | −4.6% | −13.3% | −83.9% | — | — | — | — | — |
| Free cash flow yield | −3.8% | −9.6% | −75.7% | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | 0.1% | — | — | — | — | — |
| Share price at fiscal year-end | $294.74 | $76.96 | $22.28 | $35.70 | $295.50 | $825.30 | — | — |
| Per share | ||||||||
| Revenue per share | $0.00 | $0.48 | $0.37 | — | — | — | — | — |
| Earnings per share | −$13.48 | −$10.21 | −$18.69 | — | — | — | — | — |
| Operating cash flow per share | −$11.07 | −$7.36 | −$16.85 | — | — | — | — | — |
| Free cash flow per share | −$11.07 | −$7.36 | −$16.86 | — | — | — | — | — |
| Cash per share | $26.63 | $21.92 | $12.33 | — | — | — | — | — |
| Book value per share | $39.02 | $24.88 | $10.57 | — | — | — | — | — |
| Tangible book value per share | $39.02 | $24.88 | $10.57 | — | — | — | — | — |
| Capex per share | $0.00 | $0.00 | $0.01 | — | — | — | — | — |
| Debt per share | $0.00 | $0.08 | $0.38 | — | — | — | — | — |
| Shares outstanding | 22.5M | 17.9M | 6.6M | — | — | — | — | — |
| Change in shares outstanding | +25.7% | +171.5% | — | — | — | — | — | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −45.8% | −71.0% | −169.1% | −130.4% | −62.0% | −37.7% | −129.6% | −180.7% |
| Return on invested capital (ROIC) | −154.7% | −701.0% | — | — | — | — | — | — |
| Return on assets (ROA) | −42.7% | −64.0% | −121.4% | −104.5% | −56.0% | −35.2% | −105.2% | −133.8% |
| Return on tangible assets | −32.3% | −37.8% | −140.2% | −185.1% | −57.0% | −20.4% | −74.5% | −133.8% |
| Financial health | ||||||||
| Total debt | $110,000 | $1.4M | $2.5M | $4.5M | $4.3M | $763,000 | $1.5M | — |
| Cash & short-term investments | $599.3M | $392.6M | $81.3M | $100.5M | $275.9M | $296.6M | $44.8M | $17.9M |
| Net debt | −$599.2M | −$391.2M | −$78.8M | −$96.0M | −$271.6M | −$295.8M | −$43.4M | −$17.9M |
| Debt / equity | 0.00 | 0.00 | 0.04 | 0.06 | 0.02 | 0.00 | 0.04 | — |
| Debt / assets | 0.00 | 0.00 | 0.03 | 0.04 | 0.01 | 0.00 | 0.03 | — |
| Current ratio | 10.22 | 10.77 | 5.39 | 3.12 | 7.64 | 19.23 | 6.67 | 3.72 |
| Quick ratio | 10.22 | 10.77 | 5.39 | 3.12 | 7.64 | 19.23 | 6.67 | 3.72 |
| Interest coverage | — | — | — | -513.1 | -919.4 | -326.1 | — | -178.9 |
| Working capital | $551.1M | $366.8M | $69.1M | $75.3M | $249.8M | $286.6M | $38.7M | $14.0M |
| Invested capital | $278.9M | $54.3M | −$9.1M | −$19.9M | −$20.8M | −$8.4M | −$3.2M | −$3.3M |
| Tangible asset value | $878.1M | $445.4M | $69.7M | $76.1M | $250.8M | $287.5M | $40.1M | $14.7M |
| Net current asset value | $551.1M | $366.7M | $66.6M | $71.8M | $245.5M | $286.6M | $37.9M | $14.0M |
| Graham net-net per share | $23.98 | $19.82 | $9.56 | — | — | — | — | — |
| Capital allocation | ||||||||
| Dividends paid | — | — | — | $811,000 | — | $696,000 | — | — |
| Share buybacks (net) | — | — | $137,000 | $260,000 | $0 | $30.0M | $0 | — |
| Capex / revenue | — | 0.0% | 2.0% | 30.3% | — | — | — | — |
| Capex / depreciation | 0.40 | 0.00 | 0.12 | 1.06 | 5.77 | 0.08 | 0.15 | 63.00 |
| Stock-based compensation / revenue | — | 483.6% | 1,015.8% | 1,953.1% | — | — | — | — |
| R&D / revenue | — | 1,782.0% | 3,545.8% | 10,590.2% | — | — | — | — |
| SG&A / revenue | — | 658.3% | 1,718.6% | 4,094.7% | — | — | — | — |
| Efficiency | ||||||||
| Days payables outstanding | 48,435.5 | 22.0 | 43.1 | 3,966.7 | 1,702.3 | 1,652.5 | 1,628.3 | 1,237,715.0 |
| Payables turnover | 0.01 | 16.62 | 8.47 | 0.09 | 0.21 | 0.22 | 0.22 | 0.00 |
| Asset turnover | 0.00 | 0.03 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $18.6M | $9.2M | $10.2M | $12.7M | $7.4M | $3.4M | $3.0M | $3.4M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from PRAX's annual financial statements (latest annual report filed February 19, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PRAX valuation and financial ratios
Praxis Precision Medicines earned a return on equity of −45.8% and a return on invested capital of −154.7% in fiscal 2025. It ended the year with $0.1 million of debt and $599.3 million in cash and short-term investments, a net cash position of $599.2 million.
See the PRAX income statement, the PRAX chart for price history, or the PRAX stock overview for the latest quote and news.
PRAX key metrics FAQ
What is Praxis Precision Medicines's return on equity?
Praxis Precision Medicines's return on equity (ROE) was −45.8% in fiscal 2025: net income of -$303.3 million on average shareholders' equity of $661.8 million.
What is Praxis Precision Medicines's ROIC?
Praxis Precision Medicines's return on invested capital was −154.7% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Praxis Precision Medicines have?
Praxis Precision Medicines had total debt of $0.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Praxis Precision Medicines's free cash flow yield?
Praxis Precision Medicines generated -$249.1 million of free cash flow in fiscal 2025, a free cash flow yield of −3.8% on its market value at year-end ($6.6 billion).
What is Praxis Precision Medicines's current ratio?
Praxis Precision Medicines's current ratio was 10.22 at the end of fiscal 2025: current assets were 10.22 times current liabilities.